Why the Acrux (ASX:ACR) share price is rocketing 39% higher today

The US FDA just gave this biotech the thumbs up…
The post Why the Acrux (ASX:ACR) share price is rocketing 39% higher today appeared first on The Motley Fool Australia. –

The Acrux Limited (ASX: ACR) share price has been an exceptionally strong performer on Tuesday.

In morning trade, the pharmaceutical company’s shares are up a massive 39% to 16 cents.

Why is the Acrux share price rocketing higher?

The catalyst for the rise in the Acrux share price this morning has been the release of a very positive update.

According to the release, the US Food and Drug Administration (FDA) has granted approval of the company’s generic version of Jublia (efinaconazole) topical solution.

Jublia is an FDA-approved prescription topical solution that is applied on, around, and under the toenail. It reaches the site of onychomycosis to fight the fungus that lives beneath the nail. Acrux notes that Jublia sales currently exceed US$217 million per year in the United States.

This has been a lengthy process for Acrux. The company first submitted an abbreviated new drug application (ANDA) to seek approval from the FDA in June 2018. It has also been through a patent dispute, which has since been settled.

Positively, this is the company’s second generic product that has been approved by the FDA this year. In January, Acrux was given approval for a generic version of Perrigo’s Testosterone Topical Solution. This product has a US$25 million market opportunity in the United States at present.

What now?

Following the receipt of approval from the FDA, Acrux will progress licensing negotiations with a commercial licensee to commercialise the product. This will be in accordance with the terms of the patent settlement agreement. When launched, Acrux’s product will provide a lower cost alternative to Jublia for patients in the United States.

Despite today’s impressive gain, it is worth noting that the Acrux share price is still trading slightly lower year to date. Shareholders will no doubt be hoping it is onwards and upwards from here for its shares.

The post Why the Acrux (ASX:ACR) share price is rocketing 39% higher today appeared first on The Motley Fool Australia.

Should you invest $1,000 in Acrux right now?

Before you consider Acrux, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Acrux wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

More reading

Why the Talga (ASX:TLG) share price is up 6% today
Is Cathie Wood selling Netflix stock at the worst possible time?

Top broker says the Commonwealth Bank (ASX:CBA) share price is still overvalued
Here’s why the IGO (ASX:IGO) share price is racing 9% higher today
Openpay (ASX:OPY) share price shoots higher on UK acquisition

James Mickleboro does not own any shares mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!